Vesitirim™ in Men Postmarketing Observational Study

NCT01639794 | Completed

• 1 other identifier: VES-IE-001
• Study Type: observational
• Target: 12
• Locations: 1 country
• Sites: 5

Brief Summary

This is an observational study which will look at the improvement in Lower Urinary Tract Symptoms (LUTS) in Irish men being treated with Vesitirim™ (solifenacin). Vesitirim™ is a competitive specific muscarinic receptor antagonist and has been used extensively for the treatment of OAB (Over Active Bladder) in women and has shown significant impact on urgency, frequency and incontinence in females. It is also indicated for the symptomatic treatment of urgency incontinence and/or increased urinary frequency and urgency in men. The purpose of this study is to evaluate LUTS storage symptom improvement in men with non neurogenic LUTS who have been prescribed Vesitirim™. The effect of Vesitirim (solifenacin) treatment on bothersome symptoms improvement will be measured using Over Active Bladder-q Short Form (OAB-qSF) and the Perception of Treatment Satisfaction (TS-VAS). The study will also help define some of the characteristics of the male population in Ireland who are treated with Vesitirim™ (solifenacin) as well as evaluating the effect of Vesitirim™ monotherapy or combination therapy on storage symptoms improvement (urgency, frequency and urge incontinence) using a bladder diary and IPSS (International Prostate Symptom Score). The study will also evaluate the effect of Vesitirim™ monotherapy or combination therapy on nocturia using IPSS. The impact of LUTS on quality of life will also be assessed. Data will also be collected regarding adverse drug reactions.

Conditions

Lower Urinary Tract Symptoms (LUTS); Overactive Bladder (OAB)

Keywords

LUTS (Lower Urinary Tract Symptoms); Overactive Bladder (OAB)Vesitirim; Solifenacin; Anti-muscarinic treatment; Cholinergic receptor antagonist; Storage Symptom improvement

Outcome Measures

Primary Outcomes (2)

• Change from baseline to visit 2 in Over Active Bladder questionnaire Short Form (OAB-q SF) score

  Baseline and 12 weeks

• Change from baseline to visit 2 in patient assessment of treatment satisfaction (TS-VAS)

  Baseline and 12 weeks

Secondary Outcomes (5)

• Change from baseline to visit 2 in voiding function assessed by Qmax and PVR

  Baseline and 12 weeks

• Change from baseline to visit 2 in patient perception of voiding symptoms assessed by: IPSS scores and number of urge incontinence (UUI) episodes per week

  Baseline and 12 weeks

• Change from baseline to visit 2 in storage symptoms assessed by micturition diary; number of urgency episodes per 24 hours; number of micturition per 24 hours and number of nocturia episodes per 24 hours

  Baseline and 12 weeks

• Change from baseline to visit 2 in quality of life assessed by IPSS score

  Baseline and 12 weeks

• Adverse drug reactions- incidence of acute urinary retention and urinary tract infection

  Baseline and 12 weeks

Study Arms (1)

Male patients with non-neurogenic LUTS taking VESITRIM

Male patients diagnosed with non-neurogenic Lower Urinary Tract Symptoms (LUTS) with bothersome storage disorder defined as urgency, and/or frequency and/or Urgency Urinary Incontinence (UUI)

Drug: Vesitirim™ (Solifenacin)

Interventions

Vesitirim™ (Solifenacin) DRUG

Oral

Also known as: Solifenacin

Male patients with non-neurogenic LUTS taking VESITRIM

Eligibility Criteria

• Age: 35 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients will be identified from the Consultants routine clinics and the decision to treat a patient with Vesitirim™ will be made by the treating physician prior to enrolment into this non interventional study

You may qualify if:

• Diagnosis of non-neurogenic Lower Urinary Tract Symptoms (LUTS) with bothersome storage disorder defined as urgency, and/or frequency and/or Urge Urinary Incontinence (UUI) at the discretion of the Investigator
• Eligible to start Vesitirim™ 5 or 10mg according to SmPC (Summary of Product Characteristics )

You may not qualify if:

• History of stress incontinence
• Active urinary tract infection (confirmed by positive urine analysis)
• Symptoms suggestive of severe Bladder Outlet Obstruction (BOO) defined as Qmax\<10ml/sc and/or PVR\>150ml
• History of known hypersensitivity to solifenacin succinate, oxybutynin hydrochloride, other anti-cholinergics or lactose, to any component of the dosage form or any other allergy, which, in the opinion of the Investigator contraindicates their participation
• Uncontrolled Diabetes Mellitus
• History of drug and/or alcohol abuse at the time of enrolment
• History of acute urinary retention, severe gastrointestinal obstruction (including paralytic ileus or intestinal atony or toxic megacolon or severe ulcerative colitis), myasthenia gravis, uncontrolled narrow glaucoma or swallow anterior chamber or deemed to be at risk of these conditions
• Undergoing haemodialysis or has severe renal impairment or moderate hepatic impairment and who are on treatment with a potent CYP3A4 inhibitor
• History of urogenital tumours which in the opinion of the Investigator precludes their participation in the study
• Likely to participate in another study during study period of 12 weeks from study entry

Sponsors & Collaborators

• Astellas Pharma Europe Ltd.: lead

Study Sites (5)

Site 2 - Mercy University Hospital

Cork, Ireland

Location

Site: 4 - Tallaght Hospital

Dublin, 24, Ireland

Location

Site: 1 - St James Hopsital

Dublin, 8, Ireland

Location

Site: 5 - Beaumont Hospital

Dublin, 9, Ireland

Location

Site: 3 - Sligo General Hospital

Sligo, Ireland

Location

MeSH Terms

Conditions

Lower Urinary Tract Symptoms; Urinary Bladder, Overactive

Interventions

Solifenacin Succinate

Condition Hierarchy (Ancestors)

Urological Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Urinary Bladder Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Quinuclidines; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds; Tetrahydroisoquinolines; Isoquinolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Medical Director

  Astellas Pharma Co. Ltd (APCL)

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 11, 2012
• First Posted: July 13, 2012
• Study Start: February 1, 2012
• Primary Completion: December 1, 2012
• Study Completion: December 1, 2012
• Last Updated: January 17, 2013

Record last verified: 2013-01

Locations

IE (5)